(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 47.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Arcturus Therapeutics Holdings's revenue in 2025 is $122,122,000.On average, 3 Wall Street analysts forecast ARCT's revenue for 2025 to be $2,221,077,545, with the lowest ARCT revenue forecast at $1,566,354,696, and the highest ARCT revenue forecast at $2,579,680,255. On average, 3 Wall Street analysts forecast ARCT's revenue for 2026 to be $4,097,509,808, with the lowest ARCT revenue forecast at $2,308,134,965, and the highest ARCT revenue forecast at $7,586,703,857.
In 2027, ARCT is forecast to generate $12,073,175,139 in revenue, with the lowest revenue forecast at $5,914,256,416 and the highest revenue forecast at $18,232,093,861.